General MedicationsORALGeneric
DROSPIRENONE
DROSPIRENONE
Standard Dose
3.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview DROSPIRENONE is listed in Drugs@FDA under application 216285 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DROSPIRENONE Form and strength TABLET, CHEWABLE;ORAL - 3.5MG Sponsor EXELTIS USA INC Submission history Latest submission status date: 2022-12-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview DROSPIRENONE is listed in Drugs@FDA under application 216285 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DROSPIRENONE Form and strength TABLET, CHEWABLE;ORAL - 3.5MG Sponsor EXELTIS USA INC Submission history Latest submission status date: 2022-12-19 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.